Elanco Animal Health (NYSE:ELAN) Price Target Raised to $25.00

Key Points

• Analysts at UBS Group have raised their price target for Elanco Animal Health from $19.00 to $25.00, suggesting a potential upside of 14.93% from the current stock price.
• Other analysts, including JPMorgan Chase, Stifel Nicolaus, and William Blair, have also upgraded their ratings and price targets, further indicating a consensus of Moderate Buy with an average target of $20.00.
• Elanco Animal Health recently reported an earnings per share (EPS) of $0.26, exceeding estimates and indicating a 4.8% increase in revenue year-over-year.

Elanco Animal Health (NYSE:ELAN - Get Free Report) had its price target raised by analysts at UBS Group from $19.00 to $25.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. UBS Group's price objective would suggest a potential upside of 14.93% from the company's current price.

A number of other analysts also recently issued reports on ELAN. JPMorgan Chase & Co. raised shares of Elanco Animal Health from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $18.00 to $24.00 in a research report on Tuesday, October 7th. Stifel Nicolaus increased their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the stock a "buy" rating in a research report on Wednesday, September 24th. Weiss Ratings reissued a "hold (c-)" rating on shares of Elanco Animal Health in a research report on Wednesday, October 8th. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Finally, Piper Sandler increased their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $20.00.

Elanco Animal Health Trading Up 1.6%

Shares of ELAN stock traded up $0.33 during trading hours on Monday, hitting $21.75. 4,539,188 shares of the company were exchanged, compared to its average volume of 5,924,963. The firm has a market cap of $10.81 billion, a PE ratio of 25.29, a PEG ratio of 3.93 and a beta of 1.65. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $21.82. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. The firm has a fifty day moving average of $18.90 and a 200 day moving average of $14.81.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company's revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

Hedge Funds Weigh In On Elanco Animal Health

Several institutional investors and hedge funds have recently made changes to their positions in the business. Sapient Capital LLC boosted its stake in shares of Elanco Animal Health by 5.5% during the 3rd quarter. Sapient Capital LLC now owns 134,759 shares of the company's stock valued at $2,643,000 after buying an additional 7,040 shares during the last quarter. Optas LLC bought a new position in Elanco Animal Health during the third quarter worth $295,000. Yousif Capital Management LLC lifted its stake in Elanco Animal Health by 1,333.7% during the third quarter. Yousif Capital Management LLC now owns 168,133 shares of the company's stock worth $3,386,000 after purchasing an additional 156,406 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in Elanco Animal Health by 79.3% during the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company's stock worth $43,000 after purchasing an additional 951 shares during the last quarter. Finally, Exchange Traded Concepts LLC bought a new position in Elanco Animal Health during the third quarter worth $5,282,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.